Hims & Hers Health, trading under the ticker symbol HIMS on the New York Stock Exchange, is a company focused on telemedicine and direct-to-consumer health services. Since going public via a SPAC merger in 2021, the company has attracted significant market attention for its services in sexual health, hair care, mental health, and skincare. As of mid-January 2026, HIMS shares are priced at approximately $32.20, with a market capitalization of around $7.4 billion.
Key Data Snapshot
Before diving deeper, let’s quickly review the essential data that highlights Hims & Hers Health’s market position. These figures provide a quantitative foundation for understanding the company’s fundamentals and market performance. Hims & Hers Health’s financial and trading data reveal several core characteristics: remarkable revenue growth, elevated valuation multiples, and notable share price volatility.
Recent market data indicates the company’s stock has shown considerable volatility, with a trading value of $421 million and a volume of 13.4985 million shares on January 15, 2026.
From a valuation perspective, the company has a price-to-earnings ratio (TTM) of 55.03 and a price-to-book ratio of 12.67, both above industry averages. Additionally, revenue for the first three quarters of 2025 increased by 73.79% year-over-year, while net profit rose by 7.75%, demonstrating robust growth momentum.
| Indicator Category | Specific Data | Description & Source |
|---|---|---|
| Share Price & Market Cap | Current Price: ~$32.20 | Total Market Cap: ~$7.362 billion |
| 52-Week Range: $23.97 - $72.98 | Indicates high price volatility | |
| Trading Metrics | Average Volume: ~11.51 million shares | Jan 15, 2026 Turnover: $421 million |
| Key Financial Ratios | P/E Ratio (TTM): 55.03 | EPS (TTM): $0.588 |
| P/B Ratio (MRQ): 12.67 | Book Value Per Share: $2.552 | |
| Recent Performance | Last 5 Trading Days: -7.79% | Year-to-Date: -3.82% |
Business Model: Building a Digital Health Moat
The core business model of Hims & Hers Health centers on a direct-to-consumer telemedicine platform. Through its proprietary website, telehealth platform, electronic medical records system, and integrated pharmacy, the company offers consumers a seamless, mobile-first healthcare experience.
Founded in 2017 and headquartered in San Francisco, California, Hims & Hers Health serves multiple specialties, including sexual health, hair care, mental health, skincare, and primary care. One of its latest initiatives is the planned sale of Eli Lilly’s weight-loss drug Zepbound on its telemedicine platform, part of its effort to expand its weight-loss product offerings. This move aims to provide customers with access to branded weight-loss medications and could become a future growth driver for the company.
Stock Performance and Market Volatility Analysis
Over the past year, HIMS shares have exhibited significant volatility. The 52-week price range spans from $23.97 to $72.98, a spread of $8.69. Such wide fluctuations reflect divergent market views on the digital health sector’s prospects and differing opinions about the sustainability of the company’s growth.
Recently, HIMS stock has faced downward pressure. On January 15, 2026, the share price fell 0.29% to $31.23. Over the past five trading days, the stock dropped by 7.79%, and it is down 3.82% for January overall. It’s important to note that the stock’s volatility often correlates with industry trends, quarterly earnings reports, and analyst rating adjustments. Investors considering HIMS should be fully aware of its high volatility and prepare for associated risks.
Wall Street Perspective: Divergent Price Targets
Wall Street analysts hold sharply divided views on HIMS, reflecting varying assessments of the company’s future growth prospects.
According to Fintel, the average analyst price target for Hims & Hers Health is about $46.40, representing roughly 46.41% upside from current levels. At the same time, the consensus rating leans toward "Hold."
However, there are significant differences among institutions. Bank of America analyst Allen Lutz recently lowered his price target from $32 to $29 and maintained a "Sell" rating, citing that revenue expectations for 2026 may be overly aggressive. This is currently the lowest price target on Wall Street, suggesting an 18.2% downside from current levels. Lutz acknowledges the company’s long-term growth potential but has slightly adjusted valuation multiples.
In contrast, other analysts are more optimistic. These divergent opinions make HIMS one of the most closely watched stocks in the market and provide investors with a range of analytical perspectives.
Financial Health and Growth Drivers
Financially, Hims & Hers Health demonstrates both high growth and high valuation. Revenue for the first three quarters of 2025 reached $1.73 billion, up 73.79% year-over-year, indicating strong growth momentum.
Net profit for the same period was $108 million, a 7.75% increase year-over-year. Notably, net profit growth lags far behind revenue growth, which may reflect cost pressures during the company’s expansion.
The company’s return on equity stands at 25.00%, return on assets at 0.09%, and return on sales at 0.06%. These metrics show efficient use of shareholder capital but suggest room for improvement in converting assets and sales into profit.
Looking ahead, the planned expansion of the weight-loss medication product line could become a new growth engine. Additionally, the overall expansion of the digital health sector and rising consumer acceptance of telemedicine services may continue to fuel the company’s growth.
Perspective for Digital Asset Investors
For investors in digital assets and cryptocurrency, analyzing growth stocks like HIMS offers a different perspective and diversification opportunities compared to traditional crypto assets.
Managing Volatility: HIMS shares display high volatility, similar to many cryptocurrencies. Investors experienced with such volatility may find its price behavior familiar. However, stock price swings are typically more directly tied to company fundamentals, industry trends, and macroeconomic factors.
Growth Narrative Assessment: Digital asset investors are accustomed to evaluating growth narratives based on technology and adoption. When analyzing HIMS, a similar framework applies—assessing user growth, service expansion, and market acceptance of its telemedicine platform, much like evaluating network effects in a blockchain protocol.
Diversification Value: Adding stocks like HIMS, which operate at the intersection of technology and healthcare, can provide sector diversification for portfolios heavily weighted toward digital assets.
Data-Driven Decisions: Whether in stocks or crypto, making decisions based on comprehensive data and analysis is crucial. On platforms like Gate, investors can monitor multiple asset classes and gain a broader market perspective.
With Bank of America lowering its price target to $29, Wall Street’s lowest expectation for Hims & Hers Health is now established. Meanwhile, another group of analysts has set an average price target of $44.71, projecting a very different upside scenario. The company’s 52-week share price range is $23.97 to $72.98, with the current price near the lower end of that range.
